Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8-specific signature.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
15 Jun 2023
Historique:
accepted: 02 03 2023
received: 07 04 2022
medline: 19 6 2023
pubmed: 30 3 2023
entrez: 29 3 2023
Statut: ppublish

Résumé

The chromatin activation landscape of chronic lymphocytic leukemia (CLL) with stereotyped B-cell receptor immunoglobulin is currently unknown. In this study, we report the results of a whole-genome chromatin profiling of histone 3 lysine 27 acetylation of 22 CLLs from major subsets, which were compared against nonstereotyped CLLs and normal B-cell subpopulations. Although subsets 1, 2, and 4 did not differ much from their nonstereotyped CLL counterparts, subset 8 displayed a remarkably distinct chromatin activation profile. In particular, we identified 209 de novo active regulatory elements in this subset, which showed similar patterns with U-CLLs undergoing Richter transformation. These regions were enriched for binding sites of 9 overexpressed transcription factors. In 78 of 209 regions, we identified 113 candidate overexpressed target genes, 11 regions being associated with more than 2 adjacent genes. These included blocks of up to 7 genes, suggesting local coupregulation within the same genome compartment. Our findings further underscore the uniqueness of subset 8 CLL, notable for the highest risk of Richter's transformation among all CLLs and provide additional clues to decipher the molecular basis of its clinical behavior.

Identifiants

pubmed: 36989492
pii: 495160
doi: 10.1182/blood.2022016587
doi:

Substances chimiques

Chromatin 0
Receptors, Antigen, B-Cell 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2955-2960

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 by The American Society of Hematology.

Auteurs

Maria Tsagiopoulou (M)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Centro Nacional de Análisis Genómico, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.

Vicente Chapaprieta (V)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.

Nuria Russiñol (N)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.

Beatriz García-Torre (B)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.

Nikolaos Pechlivanis (N)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Ferran Nadeu (F)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Spain.

Nikos Papakonstantinou (N)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Niki Stavroyianni (N)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Anastasia Chatzidimitriou (A)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Fotis Psomopoulos (F)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Elías Campo (E)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Spain.
Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain.

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

José Ignacio Martín-Subero (JI)

Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer, Spain.
Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH